Atlas Trials

Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Clinical trial NCT03587311 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT03587311
Sponsor
National Cancer Institute (NCI)
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Fallopian Tube Endometrioid AdenocarcinomaFallopian Tube High Grade Serous AdenocarcinomaOvarian Endometrioid AdenocarcinomaOvarian High Grade Serous AdenocarcinomaPlatinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Ovarian CarcinomaPlatinum-Resistant Primary Peritoneal CarcinomaPrimary Peritoneal High Grade Serous Adenocarcinoma
Start date
2018-10-12
Primary completion
2026-10-21
Enrollment
96

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.